Enanta Pharmaceuticals, Inc. (ENTA) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) from a sell rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

ENTA has been the subject of several other research reports. BidaskClub lowered shares of Enanta Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 11th. Royal Bank Of Canada began coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating for the company. JMP Securities upgraded shares of Enanta Pharmaceuticals from a market perform rating to an outperform rating and set a $40.00 price objective for the company in a research report on Tuesday, July 11th. J P Morgan Chase & Co restated an overweight rating and set a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Robert W. Baird raised their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a neutral rating in a research report on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Enanta Pharmaceuticals has an average rating of Buy and an average target price of $42.33.

Shares of Enanta Pharmaceuticals (ENTA) opened at 48.38 on Tuesday. The stock’s market cap is $923.57 million. The firm has a 50 day moving average of $44.16 and a 200 day moving average of $36.53. Enanta Pharmaceuticals has a one year low of $22.17 and a one year high of $48.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. During the same quarter last year, the firm posted ($0.06) EPS. The business’s revenue for the quarter was down 46.3% on a year-over-year basis. On average, equities research analysts predict that Enanta Pharmaceuticals will post $1.14 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/10/11/enanta-pharmaceuticals-inc-enta-upgraded-to-hold-at-zacks-investment-research.html.

Several large investors have recently bought and sold shares of ENTA. Texas Permanent School Fund boosted its holdings in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Texas Permanent School Fund now owns 10,146 shares of the biotechnology company’s stock worth $365,000 after buying an additional 85 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares during the period. Eqis Capital Management Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 31,565 shares of the biotechnology company’s stock worth $1,136,000 after buying an additional 173 shares during the period. Mason Street Advisors LLC boosted its holdings in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares during the period. Institutional investors own 66.06% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit